At least since the data of the DAPA-CKD and the recently published EMPA-KIDNEY trial became available, demonstrating impressive renal benefits of SGLT2 inhibition in non-diabetic CKD patients (Heerspink et al., 2020; Herrington et al., 2022), it is obvious that SGLT2 inhibitors by far exceed their initial therapeutic approach of an anti-hyperglycemic agent. Here, SLC5A2 is linked to chronic kidney disease.